Friedreich's Ataxia
- Overview
- Epidemiology
- Genetics and Molecular Mechanism
- Pathophysiology
- Clinical Features
- Diagnosis
- Treatment
- Prognosis and Quality of Life
- Key Research Papers
- Connections
- Featured Videos
1. Overview
Friedreich's ataxia (FRDA) is the most common inherited ataxia, affecting approximately 1 in 50,000 people worldwide. It is an autosomal recessive neurodegenerative disease caused by a pathological expansion of a GAA trinucleotide repeat in the first intron of the FXN gene on chromosome 9q21.11, which encodes the mitochondrial protein frataxin. Reduced frataxin levels impair iron-sulfur cluster biogenesis, cause mitochondrial iron overload, and trigger oxidative stress — ultimately destroying large neurons of the dorsal root ganglia and long ascending and descending spinal cord tracts.
The disease typically presents in childhood or early adolescence (mean onset around age 15), although adult-onset forms exist. Progressive cerebellar and sensory ataxia, loss of deep tendon reflexes, and positive Babinski signs are the cardinal neurological features. Critically, Friedreich's ataxia is a multi-system disease: roughly 80% of patients develop hypertrophic cardiomyopathy — the leading cause of premature death — and 10–30% develop diabetes mellitus. Most patients require a wheelchair within about 10 years of symptom onset.
In 2023, the FDA approved omaveloxolone (Skyclarys) as the first disease-modifying treatment for Friedreich's ataxia. Prior to this, management was entirely supportive.
2. Epidemiology
Friedreich's ataxia has a prevalence of approximately 1 in 50,000 in populations of European and Middle Eastern ancestry. The estimated carrier frequency is around 1 in 100, making it the most prevalent inherited ataxia in these populations. The disease is considerably rarer in East Asian and sub-Saharan African populations, consistent with the European origin of the ancestral GAA expansion founder haplotype.
Onset typically occurs between ages 5 and 25, with a mean onset of approximately 15 years. Roughly 25% of patients present after age 25 (late-onset Friedreich's ataxia, LOFA), and a very small proportion after age 40 (very-late-onset FRDA, VLOFA). These late-onset forms often show a milder phenotype with slower progression and retained reflexes. Both sexes are equally affected.
The global prevalence is estimated at 15,000–20,000 patients in the United States and approximately 10,000–15,000 in Europe. Because the disease shortens lifespan substantially, point-prevalence figures underrepresent the lifetime burden of the condition.
3. Genetics and Molecular Mechanism
The FXN gene spans approximately 80 kb on chromosome 9q21.11 and encodes frataxin, a 210-amino-acid mitochondrial protein. The gene contains seven exons; the GAA repeat lies within the first intron between exons 1 and 2. In normal individuals, this intronic GAA repeat is fewer than 40 copies. In Friedreich's ataxia, at least one allele (and typically both) carry expansions of 66 to more than 1,000 repeats.
The expanded GAA repeat adopts an unusual triple-helical DNA structure ("sticky DNA") that impedes transcriptional elongation through the intron, dramatically reducing frataxin mRNA and protein levels. Frataxin expression in affected patients is typically 5–30% of normal. The degree of GAA expansion on the shorter allele correlates inversely with age of onset and disease severity — shorter expansions generally produce milder, later-onset disease.
Approximately 96–98% of FRDA patients are homozygous for GAA expansions. The remaining 2–4% are compound heterozygotes who carry one GAA expansion and one point mutation, missense variant, or deletion in the other FXN allele on the opposite chromosome. The most common point mutation is p.Gly130Val, which confers a milder, slower-progressing phenotype with retained reflexes.
Because the repeat expansion acts by reducing frataxin protein levels rather than producing a toxic gain-of-function protein, strategies that increase frataxin expression — such as gene therapy, epigenetic de-repression, or mRNA stabilization — are actively pursued as therapeutics.
4. Pathophysiology
Frataxin is a small, highly conserved mitochondrial protein essential for the assembly of iron-sulfur (Fe-S) clusters. These clusters are prosthetic groups required by multiple mitochondrial electron transport chain complexes (I, II, and III) and by the enzyme aconitase in the citric acid cycle. When frataxin is deficient, Fe-S cluster assembly is impaired, and free iron accumulates within the mitochondrial matrix of affected cells.
This mitochondrial iron overload drives the production of highly reactive hydroxyl radicals via the Fenton reaction, causing progressive oxidative damage to mitochondrial DNA, lipids, and proteins. Cells with high metabolic demands and limited regenerative capacity are most vulnerable: the large sensory neurons of the dorsal root ganglia (DRG), neurons of the spinocerebellar tracts, corticospinal tracts, and — outside the nervous system — cardiomyocytes and pancreatic beta cells.
The neurodegeneration in FRDA is characterized by:
- Dorsal root ganglion neuron loss — loss of large myelinated sensory (proprioceptive and vibration) fibers → sensory ataxia and areflexia
- Posterior column degeneration — impaired fine touch, vibration, and proprioceptive signaling
- Spinocerebellar tract degeneration — ataxia of gait and limbs
- Corticospinal tract involvement — upper motor neuron signs (extensor plantar response/Babinski), spastic weakness in later stages
- Clarke's column loss — reduced cerebellar input from the spinal cord
The cerebellum itself is relatively spared early in the disease — distinguishing FRDA from cerebellar ataxias — although dentate nucleus degeneration does occur later. The mixed upper and lower motor neuron picture and prominent sensory loss are hallmarks of the disease.
5. Clinical Features
The classic presentation of Friedreich's ataxia involves progressive gait and limb ataxia developing in a child or adolescent, accompanied by a constellation of neurological and systemic findings:
Neurological Features
- Gait ataxia — wide-based, unsteady gait; the most common presenting symptom
- Limb ataxia — dysmetria on finger-nose and heel-shin testing
- Areflexia — absent deep tendon reflexes, especially at the knees and ankles (one of the earliest and most consistent findings)
- Positive Babinski sign — extensor plantar response indicating corticospinal tract involvement
- Loss of proprioception and vibration sense — impaired joint position sense; patients often cannot feel a tuning fork at the toes
- Dysarthria — scanning or slurred speech as disease progresses
- Dysphagia — in advanced disease
- Nystagmus and fixation instability — less common than in pure cerebellar ataxias
- Hearing loss — sensorineural, occurs in a minority
Skeletal and Musculoskeletal Features
- Scoliosis — in up to 80% of patients; can be severe and require surgical intervention
- Pes cavus (high-arched feet) — present in the majority; often an early sign before neurological symptoms appear
- Hammer toes
- Muscle weakness — progressive, most marked distally; contributes to foot deformities
Cardiac Features
Hypertrophic cardiomyopathy develops in approximately 80% of patients and is the leading cause of death, accounting for roughly 60% of FRDA fatalities. It typically manifests as concentric left ventricular hypertrophy. Symptoms include exertional dyspnea, palpitations, and syncope. Arrhythmias — including atrial fibrillation, heart block, and ventricular arrhythmias — are common and can cause sudden death. Some patients develop a dilated cardiomyopathy pattern in late disease.
Endocrine Features
Diabetes mellitus occurs in 10–30% of patients, caused by frataxin deficiency in pancreatic beta cells impairing insulin secretion. An additional 10–20% have impaired glucose tolerance. Diabetes significantly worsens prognosis and quality of life.
Vision and Optic Nerve
Optic atrophy occurs in approximately 25–30% of patients, often without subjective visual loss in early stages. Visual evoked potentials are frequently abnormal even when clinical vision appears intact.
6. Diagnosis
The diagnosis of Friedreich's ataxia is confirmed by genetic testing. When a patient presents with progressive ataxia, areflexia, and loss of proprioception in adolescence or early adulthood, molecular testing of the FXN gene should be the first step. The testing strategy is:
- PCR-based sizing of GAA repeats — detects homozygous GAA expansions (the most common genotype, ~97% of FRDA). Normal alleles produce a small PCR product; expanded alleles fail to amplify or produce a larger product on triplet-primed PCR.
- Sequencing of the second allele — if only one expanded allele is found on sizing, sequence the other allele for point mutations or small deletions.
Supportive investigations include:
- Nerve conduction studies / EMG — typically show absent or markedly reduced sensory nerve action potentials (SNAPs) with preserved motor conduction; consistent with large-fiber sensory neuropathy / ganglionopathy
- MRI of the spine and brain — reveals cervical and thoracic spinal cord atrophy (especially posterior columns); the cerebellum is relatively preserved early, though dentate nucleus signal changes and mild cerebellar atrophy appear in advanced disease
- Echocardiography — essential at diagnosis to evaluate for hypertrophic cardiomyopathy; should be repeated annually
- ECG — T-wave inversions and ST-segment changes are common even in asymptomatic patients; arrhythmia monitoring is important
- Glucose tolerance testing / HbA1c — screen for diabetes at diagnosis and annually
- Visual evoked potentials — assess optic nerve involvement
The Scale for Assessment and Rating of Ataxia (SARA) and the Friedreich's Ataxia Rating Scale (FARS) are validated tools used to track neurological progression in clinical trials and routine care.
7. Treatment
Disease-Modifying Therapy
In February 2023, the FDA approved omaveloxolone (Skyclarys, Reata Pharmaceuticals) — the first disease-modifying drug for Friedreich's ataxia. Omaveloxolone is a semisynthetic triterpenoid that activates the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor, upregulating antioxidant defenses and mitochondrial biogenesis. In the pivotal Phase 3 MOXIe trial (NCT02255435), omaveloxolone 150 mg/day significantly improved mFARS scores compared to placebo over 48 weeks (mean improvement of ~2 points vs. placebo-adjusted). It is approved for patients aged 16 years and older.
Cardiac Management
Cardiomyopathy management follows standard heart failure guidelines and is the most critical aspect of systemic management:
- Beta-blockers — first-line for symptomatic hypertrophic cardiomyopathy; also reduce arrhythmia risk
- ACE inhibitors or ARBs — used for patients with reduced ejection fraction or dilated cardiomyopathy
- Antiarrhythmic therapy — rate control or rhythm control for atrial fibrillation; ICD consideration for high-risk ventricular arrhythmias
- Annual echocardiography — to monitor LV wall thickness, EF, and outflow tract obstruction
Diabetes Management
Diabetes in FRDA is primarily a secretory defect; insulin therapy is often ultimately required. Standard diabetes management protocols apply. Annual HbA1c and fasting glucose monitoring are recommended.
Rehabilitative and Symptomatic Therapy
- Physical therapy — core stabilization, balance training, gait aids, fall prevention; delays wheelchair dependence
- Occupational therapy — adaptive devices for activities of daily living; handwriting aids, speech-generating devices
- Speech therapy — dysarthria management; swallowing assessment and modification
- Orthotics and orthopedic surgery — ankle-foot orthoses for foot drop; spinal fusion for severe progressive scoliosis
Investigational Therapies
- Idebenone — a synthetic analog of CoQ10; showed modest cardiac benefit in early studies but did not reach the primary neurological endpoint in the MICONOS trial; used in some countries off-label
- Gene therapy — adeno-associated virus (AAV)-mediated frataxin delivery to DRG and heart; early-phase trials ongoing (e.g., Lexeo Therapeutics LX2006)
- Epigenetic de-repression — HDAC inhibitors (e.g., nicotinamide riboside, RG2833) aim to reverse GAA repeat-induced chromatin silencing
- mRNA therapy — exogenous frataxin mRNA delivery to restore protein levels
8. Prognosis and Quality of Life
Friedreich's ataxia follows a relentlessly progressive course. The mean time to wheelchair dependence is approximately 10–15 years from symptom onset, though this varies considerably. Patients with longer GAA repeat expansions and earlier onset generally progress faster. Late-onset FRDA has a more benign trajectory and some patients retain ambulation for decades.
Life expectancy is significantly reduced. Before the era of modern cardiac care, mean survival was approximately 35 years. With active cardiac management — treating arrhythmias, managing cardiomyopathy, and preventing sudden cardiac death — survival has improved substantially. Contemporary data suggest median survival into the mid-40s to early 50s for typical FRDA, with cardiac causes accounting for approximately 59% of deaths and pneumonia (aspiration) accounting for most of the remainder.
Cognitive function is generally preserved throughout the disease, although mild executive dysfunction and slowed processing speed have been documented. Depression and anxiety are common comorbidities and significantly affect quality of life. Patients benefit from psychological support, peer support networks (e.g., Friedreich's Ataxia Research Alliance, FARA), and palliative care planning as disease advances.
9. Key Research Papers
- Campuzano V, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423–1427. PMID: 8596916
- Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256(Suppl 1):3–8. PMID: 19283312
- Tsou AY, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1–2):46–49. PMID: 21632074
- Strawser C, et al. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother. 2017;17(9):895–907. PMID: 28635367
- Lynch DR, et al. Omaveloxolone for Friedreich's ataxia: the MOXIe Part 2 randomized trial. Ann Neurol. 2021;89(2):212–225. PMID: 33159700
- Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72(2):78–90. PMID: 23334592
- Bürk K. Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias. 2017;4:4. PMID: 28239459
- Rötig A, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17(2):215–217. PMID: 9326946
- Pousset F, et al. A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol. 2015;72(11):1334–1341. PMID: 26389598
- Parkinson MH, et al. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J Neurochem. 2013;126(Suppl 1):103–117. PMID: 23808917
- Delatycki MB, Bidichandani SI. Friedreich ataxia — pathogenesis and implications for therapies. Neurobiol Dis. 2019;132:104606. PMID: 31494256
- Schmucker S, Puccio H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum Mol Genet. 2010;19(R1):R103–110. PMID: 20413654
- PubMed topic search: Friedreich ataxia frataxin
- PubMed topic search: Friedreich ataxia omaveloxolone treatment
- PubMed topic search: Friedreich ataxia cardiomyopathy
Connections
- Cerebellar Ataxia
- Peripheral Neuropathy
- Cardiomyopathy
- Diabetes
- Multiple Sclerosis
- Parkinson's Disease
- Huntington's Disease
- ALS
- Iron
- Vitamin E
- Oxidative Stress
- Scoliosis